Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)
mRNA expression, tumor heterogeneity, and response to therapy inpatients with advanced renal cell carcinoma treated with immune-basedcombinations (ARON-1α)
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell RenalCell Carcinoma: Results from the ARON-1 Study
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients withmetastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
